Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Spero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce
01:59pm, Friday, 23'rd Sep 2022 Benzinga
Evercore ISI Group raised the price target on Spero Therapeutics, Inc. (NASDAQ: SPRO) from $2 to $8. Evercore ISI Group analyst Josh Schimmer also upgraded the stock from In-Line to Outperform. Sper
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
12:47pm, Friday, 23'rd Sep 2022
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
Reddit Penny Stocks to Watch as September Ends
10:00am, Friday, 23'rd Sep 2022 PennyStocks
Check these Reddit penny stocks out for your watchlist right now
The post Reddit Penny Stocks to Watch as September Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
07:42am, Friday, 23'rd Sep 2022 Benzinga
Gainers
Spero Therapeutics, Inc. (NASDAQ: SPRO) shares jumped 167.7% to close at $2.20 on Thursday after the company announced it has entered into an exclusive license agreement with GSK for Spero's
Reddit Penny Stocks to Watch as September Ends
06:00am, Friday, 23'rd Sep 2022
Check these Reddit penny stocks out for your watchlist right now The post Reddit Penny Stocks to Watch as September Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennySto
Dow Turns Higher; Crude Oil Rises 0.7%
07:10pm, Thursday, 22'nd Sep 2022 Benzinga
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday.
The Dow traded up 0.09% to 30,211.16 while the NASDAQ fell 1% to 11,107.18. The S&P 500 also fe
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day Session
04:26pm, Thursday, 22'nd Sep 2022 Benzinga
Gainers
Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 150% to $2.0508 after the company announced it has entered into an exclusive license agreement with GSK for Spero's late-stage antibiotic asset, t
Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike Higher
04:26pm, Thursday, 22'nd Sep 2022 Benzinga
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Thursday.
The Dow traded down 0.01% to 30,180.59 while the NASDAQ fell 1.13% to 11,093.30. T
Penny Stocks To Buy Now: 3 To Watch Under $3
03:47pm, Thursday, 22'nd Sep 2022 PennyStocks
Penny stocks to buy for under $3
The post Penny Stocks To Buy Now: 3 To Watch Under $3 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Reuters
CATL's 3rd Largest Customer After Tesla, Nio Cuts Reliance On Battery Giant In Bid For Diversification
XPeng Inc (NYSE: XPEV) has diversified its battery suppliers and does not count indu
US Stocks Could Remain Jittery Thursday Over Fed Rate Hike As S&P 500, Nasdaq Futures See Volatility — McDonald's In Focus
11:23am, Thursday, 22'nd Sep 2022 Benzinga
The major U.S. index futures are flatlining, as traders are digesting the implication of the Fed's policy statement and a couple of interest rate decisions from Japan and the United Kingdom.
Fed’s d
Spero's stock jumps 188% after GSK licenses experimental antibiotic
10:53am, Thursday, 22'nd Sep 2022
Shares of Spero Therapeutics Inc. SPRO, +277.39% soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline GSK, -0.32% for its experimen
Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket
10:34am, Thursday, 22'nd Sep 2022 Benzinga
Gainers
Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem
Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement
09:56am, Thursday, 22'nd Sep 2022
Source: Willy Barton / Shutterstock.com Spero Therapeutics (NASDAQ: SPRO ) stock is rocketing higher on Thursday after the company signed a licensing agreement with GSK (NYSE: GSK ). This deal covers
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
06:00am, Thursday, 22'nd Sep 2022 GlobeNewswire Inc.
The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries
